<p>AirSculpt Technologies（纳斯达克代码：AIRS - 获取免费报告）于周五发布了季度财报。公司报告本季度每股收益为（$0.01），超出市场共识预期的（$0.02）$0.01，FiscalAI 报道。公司本季度收入为 3939 万美元，高于分析师预期的 3920 万美元。AirSculpt Technologies 的净利润率为负 7.68%，股本回报率为负 5.01%。</p>
<p>获取 <strong>AirSculpt Technologies</strong> 的提醒：</p>
<p>以下是 AirSculpt Technologies 电话会议的主要要点：</p>
<ul>
<li>AirSculpt 在第一季度报告了 <strong>3934 万美元</strong> 的收入（同比持平），并实现了两年多以来首次正增长的同中心销售，剔除伦敦后同店收入增长约 1%，环比改善 19%。</li>
<li>毛利率扩大至约 <strong>60%</strong>（服务成本为 1560 万美元），但调整后的 EBITDA 降至 <strong>330 万美元</strong>（占收入的 8.4%），由于市场营销投资的增加，销售和管理费用上升约 80 万美元。</li>
<li>资产负债表得到改善——现金为 <strong>1670 万美元</strong>，本季度偿还了 1100 万美元的债务，毛债务约为 <strong>4600 万美元</strong>，杠杆率低于 2.5 倍，管理层正在进行贷款再融资，同时保持契约合规。</li>
<li>管理层强调了 <strong>GLP-1</strong> 药物采用带来的长期机会（预计到 2030 年用户将增长至 2500 万），并正在试点皮肤紧致和皮肤去除程序（第一季度进行 150 次皮肤切除），这可能在各中心解锁超过 <strong>1 亿美元</strong> 的收入，尽管这些服务尚未成为重要的收入驱动因素。</li>
<li>公司重申 2026 财年的收入指导为 <strong>1.51 亿–1.57 亿美元</strong>，调整后的 EBITDA 为 <strong>1500 万–1700 万美元</strong>，预计第二季度将有环比改善，并且不计划在 2026 年开设任何新中心，而是优先考虑同中心的增长。</li>
</ul>
<h2>AirSculpt Technologies 股价下跌 0.8%</h2>
<p>AirSculpt Technologies 的股票在周五的午盘交易中下跌了 0.03 美元，报 3.43 美元。该股票的交易量为 1,677,564 股，而其平均交易量为 2,345,654 股。公司流动比率为 0.55，当前比率为 0.55，债务与股本比率为 0.58。该公司的市值为 2.422 亿美元，市盈率为-18.05，贝塔值为 1.99。该公司的 50 日移动平均线为 2.57 美元，200 日移动平均线为 3.51 美元。AirSculpt Technologies 的 12 个月低点为 1.51 美元，12 个月高点为 12.00 美元。</p>
<h2>AirSculpt Technologies 内部人士买卖情况</h2>
<p>在相关消息中，主要股东 Jorey Chernett 于 3 月 16 日星期一收购了 105,848 股该股票。该股票的购买均价为每股 2.43 美元，总价值为 257,210.64 美元。交易后，内部人士持有公司股票 6,592,059 股，估值约为 16,018,703.37 美元。这笔交易代表其持股比例增加了 1.63%。该收购在向 SEC 提交的文件中披露，文件可在 SEC 网站上查阅。在过去三个月中，内部人士购买了价值 1,987,624 美元的 810,150 股公司股票。公司内部人士持有公司股票的 44.60%。</p>
<h2>对 AirSculpt Technologies 的对冲基金看法</h2>
<p>一些对冲基金最近对该股票的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 30,000 美元。XTX Topco Ltd 在第四季度将其在 AirSculpt Technologies 的持仓增加了 265.2%。XTX Topco Ltd 现在拥有 179,813 股公司股票，价值 356,000 美元，此前在该期间又购买了 130,581 股。Tudor Investment Corp ET AL 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 219,000 美元。Saba Capital Management L.P.在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 620,000 美元。最后，Millennium Management LLC 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 33,000 美元。对冲基金和其他机构投资者持有公司股票的 91.54%。</p>
<h2>分析师设定新目标价</h2>
<p>另外，Wall Street Zen 在 4 月 5 日的研究报告中将 AirSculpt Technologies 的股票评级从 “卖出” 上调至 “持有”。一位投资分析师对该股票给予了持有评级，另一位则给予了卖出评级。根据 MarketBeat.com 的数据，AirSculpt Technologies 目前的平均评级为 “减持”，共识目标价为 6.00 美元。</p>
<p><strong>阅读我们最新的 AIRS 股票分析</strong></p>
<h2>AirSculpt Technologies 公司简介</h2>
<p>（获取免费报告）</p>
<p>AirSculpt Technologies, Inc 纳斯达克：AIRS 是一家专注于微创身体塑形的医疗技术公司。公司的旗舰产品 AirSculpt®平台结合了气动动力和精密微型导管，以提供脂肪去除、转移和塑形程序。AirSculpt Technologies 与公司自营和特许经营的美容外科诊所合作，提供一种简化的、基于办公室的传统抽脂替代方案。</p>
<p>通过其专有系统，AirSculpt Technologies 为消费者和医疗专业人士提供了一种集成解决方案，强调减少恢复时间、更小的切口和更可预测的结果。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 AirSculpt Technologies</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUlSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUlSUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 AirSculpt Technologies 吗？</h2>
<p>在考虑 AirSculpt Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AirSculpt Technologies 并不在名单上。</p>
<p>虽然 AirSculpt Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AIRS

<p>AirSculpt Technologies（纳斯达克代码：AIRS）报告季度每股收益为（$0.01），超出预期的（$0.02）$0.01。收入达到 3939 万美元，超过预期的 3920 万美元。公司指出净利润率为负 7.68%，股本回报率为负 5.01%。管理层强调了 GLP-1 药物采用带来的增长机会以及皮肤紧致程序的计划。公司重申 2026 财年的收入指引为 1.51 亿至 1.57 亿美元。股价下跌 0.8%，至 3.43 美元，对冲基金持有 91.54% 的股份。分析师的共识目标价为 6.00 美元</p>

<p>AirSculpt Technologies (NASDAQ:AIRS - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.01, FiscalAI reports. The company had revenue of $39.39 million during the quarter, compared to analyst estimates of $39.20 million. AirSculpt Technologies had a negative net margin of 7.68% and a negative return on equity of 5.01%.</p>
<div class="lb-trans"><p>AirSculpt Technologies（纳斯达克代码：AIRS - 获取免费报告）于周五发布了季度财报。公司报告本季度每股收益为（$0.01），超出市场共识预期的（$0.02）$0.01，FiscalAI 报道。公司本季度收入为 3939 万美元，高于分析师预期的 3920 万美元。AirSculpt Technologies 的净利润率为负 7.68%，股本回报率为负 5.01%。</p>
</div><p>Get <strong>AirSculpt Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>AirSculpt Technologies</strong> 的提醒：</p>
</div><p>Here are the key takeaways from AirSculpt Technologies' conference call:</p>
<div class="lb-trans"><p>以下是 AirSculpt Technologies 电话会议的主要要点：</p>
</div><ul>
<li>AirSculpt reported <strong>$39.4 million</strong> in Q1 revenue (flat YoY) and achieved its first positive same-center sales in over two years, with same-store revenue up ~1% excluding London and a 19% sequential improvement.</li>
<li>Gross margin expanded to about <strong>60%</strong> (cost of services $15.6M), but adjusted EBITDA fell to <strong>$3.3 million</strong> (8.4% of revenue) as SG&amp;A rose roughly $0.8M due to deliberate marketing investments.</li>
<li>The balance sheet strengthened—cash of <strong>$16.7 million</strong>, $11 million of debt repaid in the quarter, gross debt of ~ <strong>$46 million</strong>, leverage below 2.5x, and management is working on a term‑loan refinance while remaining in covenant compliance.</li>
<li>Management highlighted a large long‑term opportunity from <strong>GLP-1</strong> drug adoption (projected growth to 25M users by 2030) and is piloting skin‑tightening and skin‑removal procedures (150 skin excisions in Q1) that could unlock an estimated &gt; <strong>$100M</strong> across centers, though these services are not yet a meaningful revenue driver.</li>
<li>The company reaffirmed FY26 guidance of <strong>$151M–$157M</strong> in revenue and <strong>$15M–$17M</strong> in adjusted EBITDA, expects sequential improvement in Q2, and does not plan any de novo center openings in 2026 while prioritizing same‑center growth.</li>
</ul>
<div class="lb-trans"><ul>
<li>AirSculpt 在第一季度报告了 <strong>3934 万美元</strong> 的收入（同比持平），并实现了两年多以来首次正增长的同中心销售，剔除伦敦后同店收入增长约 1%，环比改善 19%。</li>
<li>毛利率扩大至约 <strong>60%</strong>（服务成本为 1560 万美元），但调整后的 EBITDA 降至 <strong>330 万美元</strong>（占收入的 8.4%），由于市场营销投资的增加，销售和管理费用上升约 80 万美元。</li>
<li>资产负债表得到改善——现金为 <strong>1670 万美元</strong>，本季度偿还了 1100 万美元的债务，毛债务约为 <strong>4600 万美元</strong>，杠杆率低于 2.5 倍，管理层正在进行贷款再融资，同时保持契约合规。</li>
<li>管理层强调了 <strong>GLP-1</strong> 药物采用带来的长期机会（预计到 2030 年用户将增长至 2500 万），并正在试点皮肤紧致和皮肤去除程序（第一季度进行 150 次皮肤切除），这可能在各中心解锁超过 <strong>1 亿美元</strong> 的收入，尽管这些服务尚未成为重要的收入驱动因素。</li>
<li>公司重申 2026 财年的收入指导为 <strong>1.51 亿–1.57 亿美元</strong>，调整后的 EBITDA 为 <strong>1500 万–1700 万美元</strong>，预计第二季度将有环比改善，并且不计划在 2026 年开设任何新中心，而是优先考虑同中心的增长。</li>
</ul>
</div><h2>AirSculpt Technologies Trading Down 0.8%</h2>
<div class="lb-trans"><h2>AirSculpt Technologies 股价下跌 0.8%</h2>
</div><p>Shares of AirSculpt Technologies stock traded down $0.03 during mid-day trading on Friday, hitting $3.43. The stock had a trading volume of 1,677,564 shares, compared to its average volume of 2,345,654. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm has a market cap of $242.20 million, a P/E ratio of -18.05 and a beta of 1.99. The firm has a 50-day moving average of $2.57 and a two-hundred day moving average of $3.51. AirSculpt Technologies has a 12-month low of $1.51 and a 12-month high of $12.00.</p>
<div class="lb-trans"><p>AirSculpt Technologies 的股票在周五的午盘交易中下跌了 0.03 美元，报 3.43 美元。该股票的交易量为 1,677,564 股，而其平均交易量为 2,345,654 股。公司流动比率为 0.55，当前比率为 0.55，债务与股本比率为 0.58。该公司的市值为 2.422 亿美元，市盈率为-18.05，贝塔值为 1.99。该公司的 50 日移动平均线为 2.57 美元，200 日移动平均线为 3.51 美元。AirSculpt Technologies 的 12 个月低点为 1.51 美元，12 个月高点为 12.00 美元。</p>
</div><h2>Insider Buying and Selling at AirSculpt Technologies</h2>
<div class="lb-trans"><h2>AirSculpt Technologies 内部人士买卖情况</h2>
</div><p>In related news, major shareholder Jorey Chernett acquired 105,848 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average price of $2.43 per share, with a total value of $257,210.64. Following the transaction, the insider owned 6,592,059 shares of the company's stock, valued at approximately $16,018,703.37. This trade represents a 1.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 810,150 shares of company stock worth $1,987,624. Company insiders own 44.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 Jorey Chernett 于 3 月 16 日星期一收购了 105,848 股该股票。该股票的购买均价为每股 2.43 美元，总价值为 257,210.64 美元。交易后，内部人士持有公司股票 6,592,059 股，估值约为 16,018,703.37 美元。这笔交易代表其持股比例增加了 1.63%。该收购在向 SEC 提交的文件中披露，文件可在 SEC 网站上查阅。在过去三个月中，内部人士购买了价值 1,987,624 美元的 810,150 股公司股票。公司内部人士持有公司股票的 44.60%。</p>
</div><h2>Hedge Funds Weigh In On AirSculpt Technologies</h2>
<div class="lb-trans"><h2>对 AirSculpt Technologies 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $30,000. XTX Topco Ltd boosted its position in shares of AirSculpt Technologies by 265.2% during the 4th quarter. XTX Topco Ltd now owns 179,813 shares of the company's stock worth $356,000 after purchasing an additional 130,581 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $219,000. Saba Capital Management L.P. purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $620,000. Finally, Millennium Management LLC purchased a new position in shares of AirSculpt Technologies during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 91.54% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对该股票的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 30,000 美元。XTX Topco Ltd 在第四季度将其在 AirSculpt Technologies 的持仓增加了 265.2%。XTX Topco Ltd 现在拥有 179,813 股公司股票，价值 356,000 美元，此前在该期间又购买了 130,581 股。Tudor Investment Corp ET AL 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 219,000 美元。Saba Capital Management L.P.在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 620,000 美元。最后，Millennium Management LLC 在第四季度购买了 AirSculpt Technologies 的新头寸，价值约为 33,000 美元。对冲基金和其他机构投资者持有公司股票的 91.54%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Separately, Wall Street Zen raised shares of AirSculpt Technologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, April 5th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AirSculpt Technologies currently has an average rating of &#34;Reduce&#34; and a consensus price target of $6.00.</p>
<div class="lb-trans"><p>另外，Wall Street Zen 在 4 月 5 日的研究报告中将 AirSculpt Technologies 的股票评级从 “卖出” 上调至 “持有”。一位投资分析师对该股票给予了持有评级，另一位则给予了卖出评级。根据 MarketBeat.com 的数据，AirSculpt Technologies 目前的平均评级为 “减持”，共识目标价为 6.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AIRS</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 AIRS 股票分析</strong></p>
</div><h2>AirSculpt Technologies Company Profile</h2>
<div class="lb-trans"><h2>AirSculpt Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AirSculpt Technologies, Inc NASDAQ: AIRS is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.</p>
<div class="lb-trans"><p>AirSculpt Technologies, Inc 纳斯达克：AIRS 是一家专注于微创身体塑形的医疗技术公司。公司的旗舰产品 AirSculpt®平台结合了气动动力和精密微型导管，以提供脂肪去除、转移和塑形程序。AirSculpt Technologies 与公司自营和特许经营的美容外科诊所合作，提供一种简化的、基于办公室的传统抽脂替代方案。</p>
</div><p>Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.</p>
<div class="lb-trans"><p>通过其专有系统，AirSculpt Technologies 为消费者和医疗专业人士提供了一种集成解决方案，强调减少恢复时间、更小的切口和更可预测的结果。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AirSculpt Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 AirSculpt Technologies</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUlSUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AIRS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AirSculpt Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 AirSculpt Technologies 吗？</h2>
</div><p>Before you consider AirSculpt Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AirSculpt Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AirSculpt Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 AirSculpt Technologies 并不在名单上。</p>
</div><p>While AirSculpt Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AirSculpt Technologies 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AirSculpt Technologies (NASDAQ:AIRS) 公布季度财报，每股收益比预期高出 0.01 美元